Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: Evidence in support of mitochondrial dysfunction hypothesis

Molecular Psychiatry

Volumn 21, Issue 11, 2016, Pages 1504-1510

  Yoshimi, N ^a,b   Futamura, T ^b   Bergen, S E ^c   Iwayama, Y ^d   Ishima, T ^a   Sellgren, C ^c   Ekman, C J ^c   Jakobsson, J ^e   Palsson E ^e   Kakumoto, K ^b   Ohgi, Y ^b   Yoshikawa, T ^d   Landen M ^c,e   Hashimoto, K ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

^d RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ACONITATE HYDRATASE 1; ACONITATE HYDRATASE 2; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARGININE; ARGININOSUCCINIC ACID; GLUTAMINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ISOCITRATE DEHYDROGENASE 3G; ISOCITRIC ACID; LAMOTRIGINE; LITHIUM; MESSENGER RNA; MOOD STABILIZER; NEUROLEPTIC AGENT; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BIPOLAR DISORDER; CEREBELLUM; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DORSOLATERAL PREFRONTAL CORTEX; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NONHUMAN; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BRAIN; CEREBROSPINAL FLUID; GENETICS; METABOLISM; MITOCHONDRION; PROCEDURES;

ADULT; ANIMALS; BIPOLAR DISORDER; BRAIN; GENE EXPRESSION; HUMANS; ISOCITRATE DEHYDROGENASE; ISOCITRATES; MALE; METABOLOMICS; MITOCHONDRIA; RATS;

EID: 84954490483     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.217     Document Type: Article

References (49)

1. Belmaker RH. Bipolar disorder. New Engl J Med 2004; 351: 476-486.
2. Taylor E. Managing bipolar disorders in children and adolescents. Nat Rev Neurol 2009; 5: 484-491.
3. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70: 931-939.
4. Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rossler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2014; 16: 337-353.
5. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol 2013; 48: 1601-1610.
6. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011; 129: 79-83.
7. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet 2013; 381: 1654-1662.
8. Jakobsson J, Bjerke M, Ekman CJ, Sellgren C, Johansson AG, Zetterberg H et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology 2014; 39: 2349-2356.
9. Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010; 122: 507-515.
10. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
11. Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? Trends Neurosci 2008; 31: 495-503.
12. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 2551-2565.
13. Konradi C, Sillivan SE, Clay HB. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 2012; 45: 37-47.
14. Andreazza AC, Young LT. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int J Neuropsycho-pharmacol 2014; 17: 1039-1052.
15. de Sousa RT, Machado-Vieira R, Zarate CA Jr, Manji HK. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets 2014; 18: 1131-1147.
16. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134: 714-717.
17. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009; 35: 165-176.
18. Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP et al. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci USA 2014; 111: 10761-10766.
19. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JT, Yuan P et al. Metabo-nomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 2009; 14: 269-279.
20. Perry TL, Hansen S, Gandham SS. Postmortem changes of amino compounds in human and rat brain. J Neurochem 1981; 36: 406-410.
21. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-1316.
22. Soga T, Igarashi K, Ito C, Mizobuchi K, Zimmermann HP, Tomita M. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal Chem 2009; 81: 6165-6174.
23. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. Quantitative meta-bolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2: 488-494.
24. Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M et al. Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study. PLoS One 2013; 8: e73814.
25. Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y et al. A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry 2014; 4: e379.
26. Ryden E, Johansson C, Blennow K, Landen M, Lower CSF. HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 2009; 116: 1667-1674.
27. Palsson E, Jakobsson J, Sodersten K, Fujita Y, Sellgren C, Ekman CJ et al. Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur Neuropsychopharmacol 2015; 25: 133-140.
28. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042.
29. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33.
30. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993; 88: 791-804.
31. Kim S, Webster MJ. Postmortem brain tissue for drug discovery in psychiatric research. Schizophr Bull 2009; 35: 1031-1033.
32. Kim S, Webster MJ. The Stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010; 35: 473-482.
33. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr Res 2000; 44: 151-155.
34. Allen DM. The relationship between variable selection and data augmentation, and a method for prediction. Technometrics 1974; 16: 125-127.
35. Miller AJ. Subset Selection in Regression. Chapman and Hall, CRC: Boca Raton, FL, 1974.
36. Hunziker S, Bivens MJ, Cocchi MN, Miller J, Salciccioli J, Howell MD et al. International validation of the out-of-hospital cardiac arrest score in the United States. Crit Care Med 2011; 39: 1670-1674.
37. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995; 57: 289-300.
39. Tong WH, Rouault TA. Metabolic regulation of citrate and iron by aconitases: role of iron-sulfur cluster biogenesis. Biometals 2007; 20: 549-564.
40. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013; 123: 3672-3677.
41. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3: 730-741.
42. Hartong DT, Dange M, McGee TL, Berson EL, Dryja TP, Colman RF. Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. Nat Genet 2008; 40: 1230-1234.
43. Dudley JA, Lee JH, Durling M, Strakowski SM, Eliassen JC. Age-dependent decreases of high energy phosphates in cerebral gray matter of patients with bipolar I disorder: a preliminary phosphorus-31 magnetic resonance spectro-scopic imaging study. J Affect Disord 2015; 175: 251-255.
44. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308.
45. Sun X, Wang JF, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006; 31: 189-196.
46. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
47. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994; 31: 125-133.
48. Port JD, Unal SS, Mrazek DA, Marcus SM. Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectro-scopic imaging study. Psychiatry Res 2008; 162: 113-121.
49. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61: 450-458.